Mesoblast's (ASX:MSB) cell therapy showed improved outcomes in heart disease patients based on data from a phase 3 trial, according to a Tuesday filing with the Australian bourse.
The randomized controlled study, named DREAM-HF, showed that a single intramyocardial injection of Revascor-branded allogeneic cell therapy, rexlemestrocel-L, showed an improvement in the survival of high-risk patients with ischemic heart failure and inflammation, the filing said.
Results from the trial were published in November in the peer-reviewed European Journal of Heart Failure, the filing added.
The company's shares were up almost 2% in recent Tuesday trade.
Price (AUD): $1.83, Change: $+0.03, Percent Change: +1.50%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。